{"Clinical Trial ID": "NCT02149524", "Intervention": ["INTERVENTION 1:", "- Herceptin (Trastuzumab)", "Intravenous administration", "Herceptin (trastuzuamb): Intravenous administration", "INTERVENTION 2:", "SB3 (Proposed Biosimilar Trastuzumab)", "Intravenous administration", "SB3 (proposal for biosimilar trastuzumab): intravenous administration"], "Eligibility": ["Incorporation criteria:", "Women aged 18 to 65", "The Eastern Cooperative Oncology Group (ECOG) achieved a result of 0-1", "A non-metastatic, newly diagnosed, unilateral primary breast cancer from clinical stage II to III, including inflammatory breast cancer with:", "\u2022 Tumor size 2 cm", "Invasive primary breast carcinoma confirmed by histology", "HER2-positivity confirmed by a central laboratory or a local laboratory accredited and defined as immunohistochemistry (IHC) 3+ or fluorescence hybridization in situ (FISH)+", "Known status of hormonal receptors (estrogen receptor and progesterone receptor)", "At the base, the left ventricular ejection fraction (LVEF) is 55% measured by echocardiography or multiple sheath scanning (MUGA)", "Subjects must be able to give their informed consent, which must be obtained prior to any procedure related to the study.", "- Exclusion criteria:", "Metastatic (stage IV) or bilateral or multifocal/multicentre breast cancer", "\u2022 History of any previous invasive breast carcinoma, with the exception of subjects with a history of in situ channel carcinoma (CDIS) and/or in situ lobular carcinoma (LCIS) treated only with surgery", "Previous or current history of malignant neoplasms within 5 years prior to randomization, with the exception of in situ treated curative carcinoma of the cervix, basal cell carcinoma of the skin or squamous skin carcinoma (malignant neoplasms occurring more than 5 years prior to randomization are allowed if curative treatment is only surgical)", "Previous history of radiation therapy, immunotherapy, chemotherapy or biotherapy (including HER2) Major surgery within 4 weeks prior to randomization and minor surgery within 2 weeks prior to randomization (major surgery is defined as surgery requiring general anesthesia)", "A serious heart disease that would prevent the use of trastuzumab such as:", "Documented history of congestive heart failure (CHF) (New York Heart Association, NYHA, class II or more)", "LVEF < 55% by echocardiography or MUGA scan", "Angine pectoris requiring anti-anginal medicines", "Evidence of transmural electrocardiogram infarction (ECG)", "Uncontrolled hypertension (systolic > 180 mmHg and/or diastolic > 100 mmHg)", "Clinically significant valvular heart disorders", "High-risk uncontrolled arrhythmias", "\u2022 Serious pulmonary disease sufficient to cause resting dyspnoea or requiring additional oxygen therapy", "\u2022 Known history of hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection", "Other co-occurring serious diseases that may interfere with the intended treatment, including serious cardiovascular, pulmonary, metabolic or infectious diseases", "\u2022 Known hypersensitivity to the experimental product (PI), non-IPs or any of the ingredients or excipients of IPs or non-IPs", "Known hypersensitivity to murine proteins", "known history of dihydropyrimidine dehydrogenase (DPD) deficiency", "\u00b7 Common terminology criteria of the National Cancer Institute for Adverse Events (NCI-CTCAE) v4.0", "Women of childbearing potential should agree to use contraceptive methods (see section 7.4.2) during the study and 6 months after the last dose of IP.", "\u2022 Concomitant hormonal treatment including contraceptive pills, ovarian hormone replacement for menopause, a selective oestrogen receptor modulator (SERM) either for osteoporosis or for the prevention of breast cancer", "Topics that do not want to follow the requirements of the study"], "Results": ["Performance measures:", "Complete pathological response rate (CPR) of the primary breast tumour", "[Unspecified]", "Calendar: Week 24", "Results 1:", "Title of the arm/group: Herceptin (Trastuzumab)", "Description of the arm/group: Intravenous administration", "Herceptin (trastuzuamb): Intravenous administration", "Total number of participants analysed: 398", "Type of measurement: Number", "Unit of measure: percentage of respondents 42.0", "Results 2:", "Title of arm/group: SB3 (biosimilar trastuzumab project)", "Description of the arm/group: Intravenous administration", "SB3 (proposal for biosimilar trastuzumab): intravenous administration", "Total number of participants analysed: 402", "Type of measurement: Number", "Unit of measure: percentage of respondents 51.7"], "Adverse Events": ["Undesirable Events 1:", "Total: 58/438 (13.24 per cent)", "13/438 (2.97 per cent)", "Neutropenia 5/438 (1.14%)", "Anemia 0/438 (0.00 %)", "Thrombocytopenia 0/438 (0.00 %)", "Hemolytic anaemia 1/438 (0.23%)", "Leukopenia 1/438 (0.23%)", "- Congestive heart failure 0/438 (0.00 %)", "- Superventricular tachycardia 0/438 (0.00 %)", "Myocardial infarction 1/438 (0.23%)", "Vertigo 0/438 (0.00 %)", "Adverse Events 2:", "Total: 56/437 (12.81 per cent)", "10/437 (2.29 per cent)", "Neutropenia 7/437 (1.60 %)", "Anemia 2/437 (0.46%)", "Thrombocytopenia 1/437 (0.23%)", "Hemolytic anaemia 0/437 (0.00 %)", "- Leucopenia 0/437 (0.00 %)", "Congestive heart failure 3/437 (0.69%)", "- Superventricular tachycardia 1/437 (0.23%)", "Myocardial infarction 0/437 (0.00 %)", "Vertigo 1/437 (0.23%)"]}